曹学锋，刘 杰，刘延英，马 兰

    (1.青海大学高原医学研究中心，青海 西宁 810016；2.青海大学附属医院老年科，青海 西宁 810001)

    1.Introduction

    Pulmonary arterial hypertension(PAH)is a potentially fatal vascular disease characterized by the elevation of mean pulmonary arterial pressure(mPAP)to above 25 mmHg[1].High altitude hypoxia induced PAH may lead to progressive hypoxemia and ultimately threaten the health of people living on the plateau.PAH can be initiated by hypoxia and it can also exacerbate hypoxia，thus forming a vicious circle.Hypoxia plays a pivotal role in remodeling of vascular smooth muscle cells and inflammation of small pulmonary arteries，which can have a substantial impact on the development of PAH.The circulating inflammatory markers of IL-6，IL-1 and CRP are upregulated in response to hypoxia induced inflammation at high altitude，which may also contribute to the development of PAH.Thus，both inflammatory response and pulmonary endothelial dysfunction have been implicated in the development and progression of PAH[2].

    Macrophage migration inhibitory factor(MIF)is a key pleiotropic pro-inflammatory mediator and a promising therapeutic target of PAH[3] ......